Acceder Registro /

JOSÉ MIGUEL RIVERA CARAVACA

Buscador

Gent DG, Rivera-Caravaca JM, Dobson R, Wright DJ, Lip GYH; Liverpool Centre for Cardiovascular Science. Ibrutinib use and adverse cardiovascular outcomes: A United States federated electronic medical records analysis. Eur J Intern Med. 2023 Feb;108:117-119. doi: 10.1016/j.ejim.2022.09.016. Epub 2022 Sep 24. No abstract available. PubMed PMID: 36163123.
AÑO: 2023; IF: 8.0
Lopez-Galvez R, Rivera-Caravaca JM, Mandaglio-Collados D, Orenes-Pinero E, Lahoz A, Hernandez-Romero D, Martinez CM, Carpes M, Arribas JM, Canovas S, Lip GYH, Marin F. Molecular mechanisms of postoperative atrial fibrillation in patients with obstructive sleep apnea. FASEB J. 2023 Jun;37(6):e22941. doi: 10.1096/fj.202201965RR. PubMed PMID: 37115741.
AÑO: 2023; IF: 4.8
Garcia-Tudela A, Simonelli-Munoz AJ, Gallego-Gomez JI, Rivera-Caravaca JM. Impact of the COVID-19 pandemic on stress and sleep in emergency room professionals. J Clin Nurs. 2023 Aug;32(15-16):5037-5045. doi: 10.1111/jocn.16738. Epub 2023 May 3. PubMed PMID: 37132445.
AÑO: 2023; IF: 4.2
Nadarajah R, Ludman P, Laroche C, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP; NSTEMI investigator group. Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology. Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):552-563. doi: 10.1093/ehjqcco/qcad008. PubMed PMID: 36737420; PubMed Central PMCID: PMC10495699.
AÑO: 2023; IF: 5.2
Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023 Feb;25(2):602-610. doi: 10.1111/dom.14854. Epub 2022 Sep 27. PubMed PMID: 36054168; PubMed Central PMCID: PMC10087187.
AÑO: 2023; IF: 5.8

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R